sandoglobulin 12g powder and solvent for solution for infusion bottles
csl behring uk ltd - normal immunoglobulin human - powder and solvent for solution for infusion - 12gram
sandoglobulin nf 6g/50ml solution for infusion vials
csl behring uk ltd - normal immunoglobulin human - solution for infusion - 120mg/1ml
sandoglobulin nf 12g/100ml solution for infusion vials
csl behring uk ltd - normal immunoglobulin human - solution for infusion - 120mg/1ml
adaluzis 500mg powder for concentrate for solution for infusion
correvio - ceftobiprole medocaril sodium - powder for concentrate for solution for infusion - 500 milligram(s) - other cephalosporins and penems; ceftobiprole medocaril
octagam 10% solution for infusion 1mg/10ml (20ml vial)
octapharma (ip) limited - immunoglobulin g, human - solution for infusion - immunoglobulin g, human 100 mg i/ml - immune sera and immunoglobulins
octagam 10% 10g/100ml solution for infusion bottles
octapharma ltd - normal immunoglobulin human - solution for infusion - 100mg/1ml
octagam 10% 5g/50ml solution for infusion bottles
octapharma ltd - normal immunoglobulin human - solution for infusion - 100mg/1ml
octagam 10% 2g/20ml solution for infusion vials
octapharma ltd - normal immunoglobulin human - solution for infusion - 100mg/1ml
octagam 10% 20g/200ml solution for infusion bottles
octapharma ltd - normal immunoglobulin human - solution for infusion - 100mg/1ml
imbruvica capsules 140 mg
j-c health care ltd - ibrutinib - capsules - ibrutinib 140 mg - • mantle cell lymphoma:imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.• chronic lymphocytic leukemia/small lymphocytic lymphoma :imbruvica is indicated for the treatment of adult patients, with chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll)• chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion:imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion.• waldenström’s macroglobulinemiaimbruvica is indicated for the treatment of adult patients with waldenström’s macroglobulinemia (wm).• marginal zone lymphomaimbruvica is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who require systemic therapy and have received at least one prior anti-cd20-based therapy.• chronic graft versus host diseaseimbruvica is indicated for the treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy.